SCHEMBL20119399

SCHEMBL20119399

O=C(c1c[nH]c2nc(Cl)nc(NCc3ccco3)c12)N1CCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 2/20 0.58
SMN1; SMN2 Q16637 4/20 0.46
LMNA P02545 3/20 0.42
HTT P42858 2/20 0.42
ALDH1A1 P00352 5/20 0.41
KMT2A Q03164 5/20 0.40
KDM4E B2RXH2 3/20 0.39
HSD17B10 Q99714 2/20 0.39
HPGD P15428 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
THRB P10828 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
MAPT P10636 1/20 0.38
RECQL P46063 1/20 0.38
MEN1 O00255 2/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119905 0.84 SMN1; SMN2 (0.51) RENSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL20119667 0.83 SMN1; SMN2 (0.50) RENSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL20119415 0.79 SMN1; SMN2 (0.48) RENSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL20119677 0.79 REN (0.53) RENSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL20119882 0.78 SMN1; SMN2 (0.58) RENSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL20119666 0.77 SMN1; SMN2 (0.57) SMN1; SMN2LMNAHTTALDH1A1KMT2A
SCHEMBL20119653 0.76 SMN1; SMN2 (0.54) RENSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL20120006 0.76 SMN1; SMN2 (0.56) SMN1; SMN2LMNAHTTALDH1A1KMT2A
SCHEMBL20119937 0.75 SMN1; SMN2 (0.48) SMN1; SMN2LMNAHTTALDH1A1KMT2A
SCHEMBL2897168 0.74 REN (1.00) RENSMN1; SMN2LMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 REN 4500/4885SMN1; SMN2 11/4885LMNA 639/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 REN 4500/4885SMN1; SMN2 11/4885LMNA 639/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 REN 4500/4885SMN1; SMN2 11/4885LMNA 639/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 REN 4500/4885SMN1; SMN2 11/4885LMNA 639/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 REN 4500/4885SMN1; SMN2 11/4885LMNA 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.